# Core C: Clinical Trials and Patient Advocacy

> **NIH NIH P50** · SLOAN-KETTERING INST CAN RESEARCH · 2024 · $83,959

## Abstract

CF3: Clinical Trials and Patient Advocacy Core
ABSTRACT
Sarcomas are a rare and heterogeneous group of malignancies of mesenchymal origin that affect individuals of
all ages. Sarcomas portend a poor prognosis with an estimated 5-year survival rate of 25–35% for patients with
metastatic disease. Improvements in treatment for patients with sarcoma have greatly lagged behind those
available for the epithelial and hematopoietic malignancies. Sarcoma therefore represents an area of unmet
potential in which there is a tremendous need for preclinical and clinical advancement. Clinical research on
sarcoma presents unique challenges that are inherent to serving a patient population with a variety of rare
diseases; each disease subtype has a unique biologic, pathogenic, genetic, and epigenetic basis that requires
a tailored therapeutic strategy. The conduct of clinical trials on sarcoma is a labor-intensive undertaking that
requires specific attention, initiatives, infrastructure, and expertise, apart from and in addition to those of any
major cancer center.
The main objective of the Clinical Trials and Patient Advocacy Core (CF3) is to support the translational and
clinical efforts of the MSK SPORE in Soft Tissue Sarcoma. CF3 will be jointly run by key members of the adult
and pediatric sarcoma programs at Memorial Sloan Kettering Cancer Center (MSK), ensuring the fluid
application of novel therapies across all age groups. CF3 will bridge the adult and pediatric sarcoma programs
at MSK; the basic science, translational, and clinical aspects of the various SPORE projects; and the
Administrative, Biostatistics and Bioinformatics, and Biospecimen and Pathology Cores. Additionally, CF3 will
facilitate seamless clinical collaboration with other SPOREs, cooperative/government mechanisms for clinical
trials (NCI cooperative groups), pharmaceutical companies, and patient support and advocacy groups. CF3 will
provide SPORE investigators with expertise in clinical trial development and administration, support staff for the
clinical trials, expertise in and administration of clinical trial correlates, financial support for conducting clinical
trials and performing correlative studies, and mechanisms for developing and acquiring novel therapies for rare
diseases. CF3, in close collaboration with the other SPORE cores, will provide the much-needed infrastructure
to ensure that the translational mission of the SPORE is realized across age groups in a timely, cost-effective,
and cooperative manner.
CF3 will work to facilitate the engagement and involvement of underrepresented populations in our clinical
research. CF3 will also collaborate with patient advocates to ensure that MSK’s sarcoma clinical trial protocols
best serve the needs of patients and to develop educational programming for patients and caregivers.

## Key facts

- **NIH application ID:** 10848819
- **Project number:** 2P50CA217694-06A1
- **Recipient organization:** SLOAN-KETTERING INST CAN RESEARCH
- **Principal Investigator:** William D. Tap
- **Activity code:** P50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $83,959
- **Award type:** 2
- **Project period:** 2018-09-01 → 2029-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10848819

## Citation

> US National Institutes of Health, RePORTER application 10848819, Core C: Clinical Trials and Patient Advocacy (2P50CA217694-06A1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10848819. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*